CIK 0001980845 · <br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- Open-market buys, last 90 days
- $10,051
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$10,051. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-18 | Nichols Alexander Julian Pres. & Chief Operating Ofc. | Grant or award · Stock Option (Right to Buy) | +177,935 | 177,935 | ||
| 2022-03-18 | Sullivan James Crowley Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +88,901 | 88,901 | ||
| 2021-08-20 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +155,472 | 155,472 | ||
| 2021-08-20 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +2,255 | 2,255 | ||
| 2021-08-20 | Hanson Jason David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +524,544 | 524,544 | ||
| 2021-08-20 | Hanson Jason David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +10,906 | 10,906 | ||
| 2021-08-20 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +14,205 | 14,205 | ||
| 2021-08-20 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +12,001 | 12,001 | ||
| 2020-12-14 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +1,266 | 1,266 | ||
| 2020-12-14 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +12,032 | 12,032 | ||
| 2019-07-30 | Hanson Jason David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +30,939 | 30,939 | ||
| 2018-07-09 | Hanson Jason David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +137,051 | 137,051 | ||
| 2018-03-16 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +36,618 | 36,618 | ||
| 2018-03-16 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +4,123 | 4,123 | ||
| 2017-06-15 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +3,188 | 3,188 | ||
| 2016-01-11 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +22,860 | 22,860 | ||
| 2016-01-11 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2015-05-21 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +28,876 | 28,876 | ||
| 2015-05-21 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +11,189 | 11,189 | ||
| 2013-12-04 | CHEUNG ANTHONY TZEYEW Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +52,940 | 52,940 |
Page 6 of 7 · 121 trades